PDF(Pubmed)
Abstract：
UNASSIGNED: Adenoid hypertrophy is a common childhood disease; its standard treatment is adenoidectomy. The desire for medical management is increasing due to fewer complications and more convenience. The present study investigated the effect of adding oral montelukast to mometasone nasal spray in treating adenoid hypertrophy.
UNASSIGNED: This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention.
UNASSIGNED: Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576).
UNASSIGNED: The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.
UNASSIGNED: This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention.
UNASSIGNED: Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576).
UNASSIGNED: The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.
摘要：
■腺样体肥大是一种常见的儿童疾病；其标准治疗方法是腺样体切除术。由于更少的并发症和更多的便利，对医疗管理的需求正在增加。本研究探讨了莫米松鼻喷雾剂口服孟鲁司特治疗腺样体肥大的效果。
■这是一个随机的，双盲,在转诊教学医院进行的安慰剂对照研究(德黑兰，伊朗）从2020年9月到2021年9月。纳入2至14岁的临床和放射学发现腺样体肥大的儿童。将患者随机分为两组：口服孟鲁司特莫米松鼻喷雾剂（病例组）或安慰剂莫米松（对照组）。然后，比较干预前和干预后2个月的临床评分。
■96名患者完成了研究[62.5%为男性(n=60)]。其中,病例组51例，对照组45例。干预后各组临床评分明显下降(P<0.001),但病例组的临床评分下降与对照组无显著差异(p=0.576).
■结果表明，莫米松和孟鲁司特的联合疗法在治疗腺样体肥大方面与莫米松和安慰剂具有相同的疗效。将孟鲁司特加到莫米松中没有额外的作用。
■这是一个随机的，双盲,在转诊教学医院进行的安慰剂对照研究(德黑兰，伊朗）从2020年9月到2021年9月。纳入2至14岁的临床和放射学发现腺样体肥大的儿童。将患者随机分为两组：口服孟鲁司特莫米松鼻喷雾剂（病例组）或安慰剂莫米松（对照组）。然后，比较干预前和干预后2个月的临床评分。
■96名患者完成了研究[62.5%为男性(n=60)]。其中,病例组51例，对照组45例。干预后各组临床评分明显下降(P<0.001),但病例组的临床评分下降与对照组无显著差异(p=0.576).
■结果表明，莫米松和孟鲁司特的联合疗法在治疗腺样体肥大方面与莫米松和安慰剂具有相同的疗效。将孟鲁司特加到莫米松中没有额外的作用。
